Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimiralisib in Actinic Keratosis
NCT06319794Phase 2Completed
- Sponsor
- Torqur
- Start
- Apr 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bimiralisib in actinic keratosis (AK) (2 arms), sponsored by Torqur. Primary endpoint: Change from baseline in AK lesions as measured by achieving an Investigator Global Assessment (IGA) score of 0 or 1 at Day 57. Started Apr 2024; status: completed.
02
Drugs
bimiralisib
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT06319794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06319794.